September 18, 2017
Allergy Therapeutics wins approval for PQ Grass phase II trial
Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.